Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from ABT

What next for Lucas di Grassi after retiring as a professional driver?

Di Grassi’s influence has long extended beyond the cockpit. But now he is ready to take on an even bigger role in the “second phase” of his career

Motorsport

Isabella Boylston, Power Mom en Pointe

As she prepares for her first child, the ballet star reflects on timing, ambition, and returning to the stage with a new perspective.

Marie Claire

This Boring Dividend King Might Be the Safest Pick to Add to Your Portfolio

Abbott Labs is a balance of income and growth.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

What's going wrong with the new Lamborghini Temerario GT3

High expectations, sobering reality: where the new Lamborghini Temerario GT3 is struggling, and what currently stands as its only strength

Motorsport

2026 DTM line-up: All 21 drivers for the new season

Four top drivers are leaving, but the 2026 DTM field remains star-studded: Who will step into the void, and which drivers should you keep an eye on?

Motorsport

Nurburgring 24h Qualifiers: Scherer-Audi wins as Max Verstappen's show unrewarded

After an impressive show from the F1 ace early in the race, it became a test session in preparation for the 24-hour race

Motorsport

Nurburgring 24h Qualifiers: Scherer-Audi wins as issue wrecks Verstappen's chances

After an impressive show from the F1 ace early in the race, a technical issue turned it into a test session for the 24-hour race

Autosport

Read news from The Economist, FT, and more,
with one subscription

Abbott Stock Crash: Rebound Could Be Coming Fast

Abbott Laboratories' stock price sell-off is overextended in mid-April, creating an opportunity that income investors will not want to miss.

MarketBeat

Stocks Edge Higher as Chipmakers Rebound

The S&P 500 Index ($SPX ) (SPY ) today is up +0.21%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.43%. June E-mini S&P futures (ESM26 ) are up +0.26%, and June E-mini Nasdaq futures...

Barchart

Buy the Dip: These 3 Over-$100 Stocks Just Hit New 52-Week Lows

Among the 128 new 52-week lows on the NYSE on Tuesday, there were five with share prices of $100 or higher. Not all of them are worth buying on the dip. We rate three that could be.

Barchart

DTM 2026: Full 21-car entry list

The DTM unveiled its 2026 entry list, featuring 21 cars: Check out which drivers are on this year's grid, and which are missing - plus why the field is slightly smaller than last year's

Motorsport

This Dividend King Is Down 26%. When Will It Bounce Back?

Abbott Laboratories is down 26% from its 52-week high due to a soft quarter. With 54 consecutive years of dividend hikes and guidance calling for mid-single-digit organic sales growth plus 10% EPS expansion, the Dividend King seems discounted, but the question is, can it rebound?

Barchart

Abbott Earnings Preview: What to Expect

Abbott is expected to announce its first-quarter results soon, and analysts are projecting single-digit EPS growth.

Barchart

This Dividend King With a 54-Year Dividend Streak Is Down 13% YTD. Time to Buy the Dip?

This Dividend King is suddenly on sale. Should you buy the dip?

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times UK

Who is Misty Copeland? The Ballerina Who Earned Timothée Chalamet's Standing Ovation at the Oscars After Ballet Backlash

Misty Copeland, the first Black woman promoted to principal dancer at American Ballet Theatre, returned to the stage at the 2026 Oscars with a performance that earned a standing ovation.

Motorsport

Lamborghini explains Mirko Bortolotti's move from Abt to Grasser in DTM

After a disappointing year at Abt, Mirko Bortolotti returns to Grasser as Lamborghini outlines the reasoning behind the switch involving its leading Austrian team.

Motorsport

Nicki Thiim on tough Lamborghini DTM years: “My head is still exploding”

Sleepless nights, a car that felt “special” and a duel with the strongest Huracan driver, Nicki Thiim speaks candidly about a difficult period in the DTM

Barchart

Do Wall Street Analysts Like Abbott Laboratories Stock?

While Abbott Laboratories has underperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

These Are the 3 Top Oversold S&P 500 Stocks. Should You Buy the Dip?

Abbott, Roper, and Humana are three blue-chip oversold stocks with significant upside potential for shareholders in January 2026.

MarketBeat

2 Healthcare Names That Could Get a Big Boost From Earnings

Both Abbott Laboratories and Intuitive Surgical report fourth-quarter results in late January—and both companies offer investors multiple reasons to be bullish.

Barchart

What You Need to Know Ahead of Abbott Laboratories' Earnings Release

Abbott Laboratories is expected to release its fiscal fourth-quarter earnings soon, and analysts project a low double-digit profit growth.

Barchart

This Dividend Stock Just Scored an FDA Win. Should You Buy Shares Now?

Abbott’s latest regulatory progress supports its durable growth narrative. Is now the right time to revisit ABT shares?

Benzinga

FDA Warns Against Abbott Glucose Monitor Sensors After Reports Of Over 700 Injuries, 7 Deaths

The U.S. Food and Drug Administration (FDA) in December issued a safety alert urging people with diabetes to stop using select glucose sensors made by Abbott Laboratories’ (NYSE:ABT) Diabetes Care, after the company linked the devices to seven deaths and hundreds of serious injuries.

Barchart

Is Abbott Laboratories Stock Underperforming the S&P 500?

Abbott Laboratories has lagged behind the S&P 500 in recent months as well as over the past year, yet analysts remain strongly bullish on the stock’s prospects.

Barchart

Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here?

Exact Sciences stock rallies as Abbott announces a $21 billion deal to acquire to the molecular diagnostics firm. Here’s why EXAS shares are unlikely to push any higher in 2026.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.